Andreas Seeber

List of Publications by Year
in descending order

63	949	567281 15	501196 28
papers	citations	h-index	g-index

64	64	64	1587
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Longitudinal analysis of 2293 NSCLC patients: A comprehensive study from the TYROL registry. Lung Cancer, 2015, 87, 193-200.	2.0	115
2	Curcumin: New Insights into an Ancient Ingredient against Cancer. International Journal of Molecular Sciences, 2019, 20, 1808.	4.1	109
3	Molecular Profiling of Appendiceal Adenocarcinoma and Comparison with Right-sided and Left-sided Colorectal Cancer. Clinical Cancer Research, 2019, 25, 3096-3103.	7.0	65
4	Molecular profile of BRCA-mutated biliary tract cancers. ESMO Open, 2020, 5, e000682.	4.5	64
5	Concise Review: Aggressive Colorectal Cancer: Role of Epithelial Cell Adhesion Molecule in Cancer Stem Cells and Epithelial-to-Mesenchymal Transition. Stem Cells Translational Medicine, 2018, 7, 495-501.	3.3	59
6	Comprehensive Genomic Profiling of Gastroenteropancreatic Neuroendocrine Neoplasms (GEP-NENs). Clinical Cancer Research, 2020, 26, 5943-5951.	7.0	55
7	High <scp>IDO</scp>â€1 expression in tumor endothelial cells is associated with response to immunotherapy in metastatic renal cell carcinoma. Cancer Science, 2018, 109, 1583-1591.	3.9	53
8	The impact of ARID1A mutation on molecular characteristics in colorectal cancer. European Journal of Cancer, 2020, 140, 119-129.	2.8	37
9	Molecular characteristics of BRCA1/2 and PALB2 mutations in pancreatic ductal adenocarcinoma. ESMO Open, 2020, 5, e000942.	4.5	26
10	High indoleamine-2,3-dioxygenase 1 (IDO) activity is linked to primary resistance to immunotherapy in non-small cell lung cancer (NSCLC). Translational Lung Cancer Research, 2021, 10, 304-313.	2.8	23
11	The Emerging Role of Liquid Biopsy in Gastric Cancer. Journal of Clinical Medicine, 2021, 10, 2108.	2.4	20
12	Large-scale analysis of KMT2 mutations defines a distinctive molecular subset with treatment implication in gastric cancer. Oncogene, 2021, 40, 4894-4905.	5.9	19
13	Molecular profiling of signet-ring-cell carcinoma (SRCC) from the stomach and colon reveals potential new therapeutic targets. Oncogene, 2022, 41, 3455-3460.	5.9	19
14	Incidental Diagnosis of Asymptomatic Nonâ€“Small-Cell Lung Cancer: A Registry-Based Analysis. Clinical Lung Cancer, 2016, 17, 62-67.e1.	2.6	18
15	Prostate cancer changes in clinical presentation and treatments in two decades: an Italian population-based study. European Journal of Cancer, 2016, 67, 91-98.	2.8	17
16	Treatment According to Molecular Profiling in Relapsed/Refractory Cancer Patients: A Review Focusing on Latest Profiling Studies. Computational and Structural Biotechnology Journal, 2019, 17, 447-453.	4.1	17
17	Comprehensive Analysis of R-Spondin Fusions and RNF43 Mutations Implicate Novel Therapeutic Options in Colorectal Cancer. Clinical Cancer Research, 2022, 28, 1863-1870.	7.0	16
18	Treatment of patients with refractory metastatic cancer according to molecular profiling on tumor tissue in the clinical routine: an interim-analysis of the ONCO-T-PROFILE project. Genes and Cancer, 2016, 7, 301-308.	1.9	15

#	Article	IF	Citations
19	FGFR Pathway Inhibition in Gastric Cancer: The Golden Era of an Old Target?. Life, 2022, 12, 81.	2.4	15
20	Towards Molecular Profiling in Multiple Myeloma: A Literature Review and Early Indications of Its Efficacy for Informing Treatment Strategies. International Journal of Molecular Sciences, 2018, 19, 2087.	4.1	14
21	Molecular Characterization of Appendiceal Goblet Cell Carcinoid. Molecular Cancer Therapeutics, 2020, 19, 2634-2640.	4.1	14
22	Detection of soluble EpCAM (sEpCAM) in malignant ascites predicts poor overall survival in patients treated with catumaxomab. Oncotarget, 2015, 6, 25017-25023.	1.8	14
23	Correlations between peripheral blood biomarkers and clinical outcomes in advanced non-small cell lung cancer patients who received immunotherapy-based treatments. Translational Lung Cancer Research, 2021, 10, 4477-4493.	2.8	14
24	Deregulated glutamate to pro-collagen conversion is associated with adverse outcome in lung cancer and may be targeted by renin-angiotensin-aldosterone system (RAS) inhibition. Lung Cancer, 2021, 159, 84-95.	2.0	12
25	Targeting BRCA and DNA Damage Repair Genes in GI Cancers: Pathophysiology and Clinical Perspectives. Frontiers in Oncology, 2021, 11, 662055.	2.8	12
26	Impact and Novel Perspective of Immune Checkpoint Inhibitors in Patients with Early and Intermediate Stage HCC. Cancers, 2022, 14, 3332.	3.7	11
27	WRN-Mutated Colorectal Cancer Is Characterized by a Distinct Genetic Phenotype. Cancers, 2020, 12, 1319.	3.7	10
28	Molecular differences between lymph nodes and distant metastases compared with primaries in colorectal cancer patients. Npj Precision Oncology, 2021, 5, 95.	5.4	9
29	Molecular landscape of colorectal cancers harboring R-spondin fusions.. Journal of Clinical Oncology, 2019, 37, 3588-3588.	1.6	7
30	High CXCR4 expression in pancreatic ductal adenocarcinoma as characterized by an inflammatory tumor phenotype with potential implications for an immunotherapeutic approach.. Journal of Clinical Oncology, 2021, 39, 4021-4021.	1.6	6
31	Impact of MLH1, PMS2, MSH2, and MSH6 alterations on tumor mutation burden (TMB) and PD-L1 expression in 1,057 microsatellite instability-high (MSI-H) tumors.. Journal of Clinical Oncology, 2018, 36, 3572-3572.	1.6	6
32	Cost-comparison analysis of a multiplatform tumour profiling service to guide advanced cancer treatment. Cost Effectiveness and Resource Allocation, 2019, 17, 23.	1.5	5
33	Treatment According to a Comprehensive Molecular Profiling Can Lead to a Better Outcome in Heavily Pretreated Patients With Metastatic Cancer. Cancer Journal (Sudbury, Mass), 2019, 25, 73-79.	2.0	5
34	Characteristics of colorectal cancer (CRC) patients with BRCA1 and BRCA2 mutations.. Journal of Clinical Oncology, 2019, 37, 606-606.	1.6	5
35	The DNA damage repair-related gene PKMYT1 is a potential biomarker in various malignancies. Translational Lung Cancer Research, 2021, 10, 4600-4616.	2.8	5
36	What's new in small cell lung cancer â€“ extensive disease? An overview on advances of systemic treatment in 2016. Future Oncology, 2017, 13, 1427-1435.	2.4	4

#	Article	IF	Citations
37	The Prognostic Impact of Comorbidities in Patients with De-Novo Diffuse Large B-Cell Lymphoma Treated with R-CHOP Immunochemotherapy in Curative Intent. Journal of Clinical Medicine, 2020, 9, 1005.	2.4	3
38	Olaratumab plus anthracyline in advanced/metastatic soft tissue sarcoma. Wiener Klinische Wochenschrift, 2021, 133, 21-25.	1.9	3
39	Peritoneal or mesenteric tumours revealing histiocytosis. BMJ Open Gastroenterology, 2021, 8, e000622.	2.7	3
40	Resistance in gastrointestinal stromal tumors. Memo - Magazine of European Medical Oncology, 2019, 12, 140-143.	0.5	2
41	Genomic Alterations and Their Implications on Survival in Nonmetastatic Colorectal Cancer: Status Quo and Future Perspectives. Cancers, 2020, 12, 2001.	3.7	2
42	Multiomic analysis to reveal distinct molecular profiles of uterine and nonuterine leiomyosarcoma.. Journal of Clinical Oncology, 2021, 39, 11555-11555.	1.6	2
43	Disseminated focal 18F-fluoro-deoxyglucose uptake upon granulocyte colony-stimulating factor therapy mimicking malignant bone infiltration: case report of a patient with very severe aplastic anemia. Therapeutic Advances in Hematology, 2020, 11, 204062072097761.	2.5	2
44	Circadian clock gene PER1 mutations in colorectal cancer (CRC).. Journal of Clinical Oncology, 2018, 36, 12106-12106.	1.6	2
45	The tumor microenvironment and immune infiltration landscape of KRAS mutant pancreatic ductal adenocarcinomas (PDAC) compared to colorectal adenocarcinomas (CRC).. Journal of Clinical Oncology, 2022, 40, 4142-4142.	1.6	2
46	CXCR4 overexpression: An indicator of poor survival and predictor of response to immunotherapy in patients with metastatic colorectal cancer.. Journal of Clinical Oncology, 2022, 40, 3546-3546.	1.6	2
47	Comprehensive genomic and transcriptomic characterization of small bowel adenocarcinoma.. Journal of Clinical Oncology, 2022, 40, 4018-4018.	1.6	2
48	Reply. Clinical Lung Cancer, 2016, 17, e187.	2.6	1
49	Benefit of second-line therapy for advanced esophageal squamous cell carcinoma: a tri-center propensity score analysis. Therapeutic Advances in Medical Oncology, 2021, 13, 175883592110399.	3.2	1
50	Rare lung cancersâ€"Primary pulmonary leiomyosarcoma: AÂcase report. Memo - Magazine of European Medical Oncology, 2021, 14, 392-396.	0.5	1
51	High SARSâ€CoVâ€2 vaccination coverage but still room for improvement in patients with haemophila: A singleâ€centre analysis. Haemophilia, 2022, 28, .	2.1	1
52	Age as a factor in the molecular landscape and the tumor-microenvironmental signature of osteosarcoma.. Journal of Clinical Oncology, 2022, 40, 11525-11525.	1.6	1
53	Surfaceome profiling to reveal unique therapeutic vulnerabilities in transcriptional subtypes of small cell lung cancer (SCLC).. Journal of Clinical Oncology, 2022, 40, 8515-8515.	1.6	1
54	Differential expression of somatostatin receptor (SSTR) subtypes across a spectrum of neuroendocrine neoplasms (NENs).. Journal of Clinical Oncology, 2022, 40, 3071-3071.	1.6	1

#	Article	IF	Citations
55	The first meeting of the Austrian Expert Panel for Molecular Cancer Profiling. Memo - Magazine of European Medical Oncology, 2017, 10, 255-258.	0.5	0
56	Diagnostic and therapeutic management of sarcoma patients. Memo - Magazine of European Medical Oncology, 2020, 13, 141-142.	0.5	0
57	Case report: successful perioperative management of patients with haemophilia A using an extended half-life factor VIII (Efmoroctocog alfa) during neurosurgical procedures. Therapeutic Advances in Hematology, 2021, 12, 204062072199368.	2.5	0
58	Detection of soluble EpCAM in malignant ascites to predict overall survival in patients treated with catumaxomab.. Journal of Clinical Oncology, 2014, 32, e15173-e15173.	1.6	0
59	Molecular analyses of left- and right-sided tumors in adolescents and young adults (AYA) with colorectal cancer (CRC).. Journal of Clinical Oncology, 2018, 36, 3577-3577.	1.6	0
60	Molecular characterization of appendiceal cancer and comparison with right-sided (R-CRC) and left-sided colorectal cancer (L-CRC).. Journal of Clinical Oncology, 2018, 36, 3611-3611.	1.6	0
61	Comprehensive genomic profiling of 724 gastroenteropancreatic neuroendocrine tumors (GEP-NETs).. Journal of Clinical Oncology, 2018, 36, 4098-4098.	1.6	0
62	Molecular profile of hepatocellular carcinoma (HCC) in older versus younger adults: Does age matter?. Journal of Clinical Oncology, 2022, 40, 477-477.	1.6	0
63	The prognostic significance of TP53 mutations in patients with right-sided and left-sided colorectal cancer.. Journal of Clinical Oncology, 2022, 40, 3589-3589.	1.6	0